Abstract
Immunoliposome, a type of liposome on which cancer cell specific antibody is conjugated, is expected as ideal drug delivery system which exhibits superior anticancer effect with lower side effect rather compared to conventional anticancer drugs owing to concentrating the drug or gene fragment onto cancer cells. In this article, we will show the result of non-clinical study focusing on the construction and the pharmacology of novel immunoliposorne, MCC-465, on which newly established human monoclonal antibody is conjugated. Furthermore, we will introduce the points which require special attention in developing the immunoliposome by discussing the result of first phase I clinical study of MCC-465.
